How Weight Loss Medications Differ

By the Body Reset Blog Team — Independent research on physician-supervised telehealth programs

The phrases start to blur together after the first few searches, GLP-1 agonist, lipase inhibitor, anorectic, and somewhere between a Reddit thread and a clinical abstract, the question shifts from “what are these?” to “what actually separates one class from another, and why does it matter for the telehealth intake form you’re about to fill out?”

Medications prescribed through telehealth weight loss programs are not a single category of drug. They fall into distinct classes with entirely different mechanisms. The core distinction is this: some medications act on brain pathways that regulate appetite and cravings, while others work in the digestive system to physically alter how the body absorbs nutrients, and still others mimic hormones that orchestrate satiety and the rate at which the stomach empties. A clinician selects from these classes based on a person’s medical history, co-existing conditions, and what a telehealth intake evaluation reveals, never on a universal ranking of effectiveness, because no such ranking exists that applies to everyone. Understanding the classes, however, gives you a far sharper lens for the conversation you’ll have with a licensed provider, whether you’re researching what to ask or simply trying to make sense of the enrollment flow you just started.

The Appetite-Signaling Group: GLP-1 and GIP Receptor Agonists

This is the group most people are reading about, and it operates by imitating incretin hormones the body already produces. GLP-1 (glucagon-like peptide-1) receptor agonists, and their newer dual-agonist counterparts that also bind to GIP receptors, slow gastric emptying and signal satiety to the brain. The result is a neurohormonal shift that feels, for many people, like a genuine reduction in the mental noise around food. That framing matters: these are not stimulants, and they do not accelerate metabolism like a classic thermogenic drug. The pattern across the platforms we reviewed is that medications in this class are overwhelmingly the ones at the center of current telehealth memberships, precisely because the weekly injection format fits the direct-to-patient pharmacy model well.

Clinicians prescribe them only after lab work and a medical evaluation, because they carry risks, nausea, vomiting, pancreatitis, gallbladder complications, and a boxed warning regarding thyroid C-cell tumors based on animal studies, as detailed by the FDA’s drug safety communications. Lab screening for kidney function, pancreatic history, and family medical background is standard; a telehealth platform cannot supply these drugs without that step, nor would a licensed clinician skip it.

The Digestive-Enzyme Gatekeepers: Lipase Inhibitors

Where GLP-1 agonists work upstream at the brain-gut signaling level, lipase inhibitors work directly at the moment of nutrient absorption. They block the enzyme pancreatic lipase, which means a fraction of dietary fat passes through the gut unabsorbed. The tradeoff is immediate, this mechanism only engages during meals that contain fat, and the undigested fat can produce gastrointestinal effects that require strict dietary adherence to manage. The medication does not enter the bloodstream in significant concentrations, which makes its drug-interaction profile different from centrally acting agents, but the requirement for clinician oversight does not disappear: the risk of fat-soluble vitamin deficiencies and liver enzyme changes means periodic monitoring is not optional. Clinicians sometimes discuss this class when a patient’s medical history makes systemic appetite-signaling drugs less appropriate, but the decision rests on a full health history review.

The Brain-Pathway Stimulants and Combination Agents

A third category comprises medications that affect appetite through direct action on central nervous system pathways. Some are stimulants in the amphetamine-like family; others combine two older drugs, one a neurotransmitter reuptake inhibitor, the other an opioid antagonist, to modulate both appetite and reward-driven eating patterns. The stimulant class has controlled-substance status, and for good reason: blood pressure elevation, heart rate changes, and dependence risk shape every clinical conversation about them. Telehealth platforms that can legally prescribe these agents still require blood pressure readings, a cardiovascular health history, and often more frequent check-ins than a GLP-1-focused program demands.

The table below maps out the structural differences in how these classes operate:

Which class a telehealth clinician considers suitable depends on documented history, not platform marketing. This layered decision process is why the intake questionnaire on nearly every platform asks about past surgeries, cardiovascular events, mental health diagnoses, and current medications. That form is the clinical filter, and the best telehealth weight loss platforms compared differ in how thorough their evaluation is, not just in their monthly subscription structure.

Why the Intake Form Asks What It Does

Cross-class prescribing risk is the reason the medical questionnaire on a telehealth portal is longer than you expect. A clinician cannot safely prescribe a stimulant-class appetite suppressant to someone whose health history includes uncontrolled hypertension, nor a GLP-1 agonist to someone with a personal or family history of medullary thyroid carcinoma. When a platform also offers combination agents, the screening needs to extend into mental health history because the naltrexone component in some oral formulations interacts with opioid-containing medications and the bupropion component lowers the seizure threshold. This is not administrative friction, it is the doctor working through the exact differential that makes medication classes clinically meaningful. How telehealth weight loss works from the clinician’s perspective is a sequence of narrowing possibilities against a health record until a licensed professional arrives at a treatment plan that fits the individual, not the advertisement.

FAQ

Why can’t a telehealth platform prescribe every weight loss medication class to everyone?

Because each class has exclusion criteria that a clinician must verify through health history and lab work. A platform cannot bypass these checks without endangering patient safety, and its medical team is liable for prescriptions that violate clinical guidelines.

Do GLP-1 medications work faster than lipase inhibitors?

The concept of “faster” implies a measurable comparison, and no trial exists that compares all classes head-to-head for speed across every population. Appetite-signaling agents act on neurohormonal satiety cues, while lipase inhibitors act on fat absorption, they operate on different biological timelines and cannot be compared in terms of a universal speed metric.

What determines which class a telehealth clinician will start with?

The starting point is the intake lab work, the comprehensive health history questionnaire, and the clinician’s evaluation of a patient’s personal and family medical profile. No class is a default, every prescription is the result of matching clinical data to a drug’s mechanism and risk profile.

This article is educational content, not medical advice, and is not a substitute for a consultation with a licensed clinician. Prescription treatments require a medical evaluation, and every telehealth platform mentioned here requires one before prescribing anything. Never start, stop, or change a medication without talking to your doctor.